Attorney General Bill Schuette announced that Michigan will benefit from a $105 million multi-state settlement to resolve allegations that GlaxoSmithKline unlawfully promoted its asthma drug, Advair, and antidepressant drugs, Paxil and Wellbutrin. The Complaint and Consent Judgment filed Wednesday in Ingham County Circuit Court alleges that GlaxoSmithKline violated state consumer protection laws by misrepresenting the uses and qualities of these drugs. Schuette says Michigan will get more than two-point-six million dollars of the settlement, which will go toward the State’s General Fund. The Consent Judgment requires GSK to continue its Patient First Program for five years, through March 2019. The program reduces financial incentives for sales representatives to engage in deceptive marketing.